| 2020-02-21 15:03:02|
ESPR 15:03 02/21 02/21/20
Esperion selloff on Nexletol approval attributed to adverse event profile
The selloff in shares of Esperion Therapeutics following news of the FDA approving its cholesterol treatment Nexletol is being attributed to the concerns over the drug's adverse event profile. CNCB's Meg Tirrell tweeted, "$ESPR drug approved, stock drops 7% - Jefferies' @therealJHOLZ cites investor concern about adverse event profile." Shares of Esperion are down 7%, or $4.78, to $63.57 in afternoon trading.